The multicenter, prospective WE-TRUST study will evaluate the ability of the company's interventional Direct to Angio Suite workflow to diagnose, plan, and treat stroke patients without the need for an initial CT or MRI scan.
The open-label, blinded end point trial will be performed primarily on Philips' Azurion image-guided therapy system at eight stroke sites in Europe and the U.S. and include more than 460 patients. The primary end point of the trial is the cognitive function of the patients three months after the procedure. Philips plans to launch the trial in the first half of 2020, with a target completion date of 2022.
In other company news, Philips' Azurion recently performed its one millionth procedure. The system launched in 2017. The milestone procedures occurred at GZA Ziekenhuizen in Antwerp, Belgium.
Copyright © 2019 AuntMinnie.com